The DEA Rescinds Proposal to Ban Five Psychedelics
Post# of 138
(Total Views: 167)
Posted On: 08/01/2022 5:32:56 PM
The DEA Rescinds Proposal to Ban Five Psychedelics
The Drug Enforcement Administration (DEA) recently withdrew a proposal to ban certain psychedelics, stating that it had instead decided to request for an updated review of the psychedelic compounds from the Department of Health and Human Services (DHHS). The DEA had first proposed that the DiPT, 5-MeO-DET, 5-MeO-MiPT, 5-MeO-AMT and 4-OH-DiPTtryptamines be scheduled earlier in the year. Tryptamines are psychedelic and hallucinogenic drugs that cause users to experience hallucinations as well as euphoria.
However, after the announcement, the agency faced criticism on the matter and received hundreds of messages opposing the change and asking for a hearing. Through its own administrative court, the DEA decided to hold a hearing on the matter before prohibition could be approved. Following the agency’s recent announcement, however, the hearing, which was set for Aug. 22, 2022, has been called off.
This decision is being celebrated by both advocates and researchers, who argue that scheduling the tryptamines as Schedule I substances would impede research into their therapeutic potential. However, it is important to note that it isn’t clear how long the Department of Health and Human Services will take to carry out a scientific review of these substances.
Additionally, it isn’t guaranteed that the department will recommend that the substances be placed in a less-prohibitive schedule or even remain unscheduled. Despite this, the cancellation does afford researchers more time to conduct studies into the compounds without the taxing barriers imposed by a Schedule I classification.
With regard to the five tryptamines, the DEA revealed that it had considered recommendations made by the DHHS before it submitted it scheduling proposal. The recommendations noted that the compounds were being abused because of their hallucinogenic properties.
In its latest notice, the DEA explained that the agencies had identified hospitalization cases associated with the use of some of the tryptamines, citing a death where 5-MeO-AMT was found in the individual’s system. However, the presence of an antidepressant and alcohol led the DEA to admit that the role the tryptamine played in the person’s death was unclear.
On a separate note, the DEA is also being sued over refusing to allow a physician to treat patients with terminal illnesses using psilocybin therapy in accordance with state and federal Right to Try laws. In addition, the agency is being sued over repeatedly delaying to process requests for public records related to cannabis and psychedelics.
This change of heart regarding the plan to ban a handful of psychedelic compounds could signal that the DEA is becoming more responsive to the feedback and sentiments of the scientific community and other stakeholders such as Silo Pharma Inc. (OTCQB: SILO) that would like to see the industry grow under a regulatory framework which addresses public health concerns while allowing industry players to be innovative.
NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTCQB: SILO) are available in the company’s newsroom at https://ibn.fm/SILO
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
The Drug Enforcement Administration (DEA) recently withdrew a proposal to ban certain psychedelics, stating that it had instead decided to request for an updated review of the psychedelic compounds from the Department of Health and Human Services (DHHS). The DEA had first proposed that the DiPT, 5-MeO-DET, 5-MeO-MiPT, 5-MeO-AMT and 4-OH-DiPTtryptamines be scheduled earlier in the year. Tryptamines are psychedelic and hallucinogenic drugs that cause users to experience hallucinations as well as euphoria.
However, after the announcement, the agency faced criticism on the matter and received hundreds of messages opposing the change and asking for a hearing. Through its own administrative court, the DEA decided to hold a hearing on the matter before prohibition could be approved. Following the agency’s recent announcement, however, the hearing, which was set for Aug. 22, 2022, has been called off.
This decision is being celebrated by both advocates and researchers, who argue that scheduling the tryptamines as Schedule I substances would impede research into their therapeutic potential. However, it is important to note that it isn’t clear how long the Department of Health and Human Services will take to carry out a scientific review of these substances.
Additionally, it isn’t guaranteed that the department will recommend that the substances be placed in a less-prohibitive schedule or even remain unscheduled. Despite this, the cancellation does afford researchers more time to conduct studies into the compounds without the taxing barriers imposed by a Schedule I classification.
With regard to the five tryptamines, the DEA revealed that it had considered recommendations made by the DHHS before it submitted it scheduling proposal. The recommendations noted that the compounds were being abused because of their hallucinogenic properties.
In its latest notice, the DEA explained that the agencies had identified hospitalization cases associated with the use of some of the tryptamines, citing a death where 5-MeO-AMT was found in the individual’s system. However, the presence of an antidepressant and alcohol led the DEA to admit that the role the tryptamine played in the person’s death was unclear.
On a separate note, the DEA is also being sued over refusing to allow a physician to treat patients with terminal illnesses using psilocybin therapy in accordance with state and federal Right to Try laws. In addition, the agency is being sued over repeatedly delaying to process requests for public records related to cannabis and psychedelics.
This change of heart regarding the plan to ban a handful of psychedelic compounds could signal that the DEA is becoming more responsive to the feedback and sentiments of the scientific community and other stakeholders such as Silo Pharma Inc. (OTCQB: SILO) that would like to see the industry grow under a regulatory framework which addresses public health concerns while allowing industry players to be innovative.
NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTCQB: SILO) are available in the company’s newsroom at https://ibn.fm/SILO
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
(0)
(0)